Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 5/20 | 0.35 |
| ▸ | ALDH5A1 | P51649 | 3/20 | 0.33 |
| ▸ | ABAT | P80404 | 3/20 | 0.33 |
| ▸ | KIF11 | P52732 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.31 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.31 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23501057 | 0.69 | ALDH1A1 (0.53) | ALDH1A1HSD17B10TDP1PTGS2KDM4E | |
| SCHEMBL3775818 | 0.69 | ALDH1A1 (0.57) | ALDH1A1HSD17B10TDP1KDM4ECYP2A6 | |
| SCHEMBL27855319 | 0.68 | ALDH1A1 (0.52) | ALDH1A1HSD17B10TDP1PTGS2KDM4E | |
| SCHEMBL6174530 | 0.67 | ALDH1A1 (0.46) | ALDH1A1HSD17B10TDP1KDM4ERAB9A | |
| SCHEMBL20312718 | 0.67 | ALDH1A1 (0.41) | ALDH1A1HSD17B10TDP1PTGS2KDM4E | |
| SCHEMBL5515460 | 0.67 | ALDH1A1 (0.42) | ALDH1A1HSD17B10TDP1PTGS2KDM4E | |
| SCHEMBL23775788 | 0.66 | ALDH1A1 (0.59) | ALDH1A1HSD17B10TDP1PTGS2KDM4E | |
| SCHEMBL28230706 | 0.66 | ALOX5 (0.64) | ALDH1A1HSD17B10TDP1RAB9AKIF11 | |
| SCHEMBL30576999 | 0.65 | ALDH1A1 (0.77) | ALDH1A1HSD17B10TDP1KDM4ERAB9A | |
| SCHEMBL210494 | 0.65 | ALDH1A1 (0.77) | ALDH1A1HSD17B10TDP1KDM4ERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9789120-B2 | Male contraceptive compositions and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9789120-B2 | Male contraceptive compositions and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170145013-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20160317547-A1 | Male Contraceptive Compositions And Methods Of Use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-11-03 | — | — | US | disclosed |
| US-20160317547-A1 | Male Contraceptive Compositions And Methods Of Use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-11-03 | — | — | US | disclosed |
| US-9320741-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-9320741-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20150150885-A1 | Compositions and Methods for Treating Neoplasia, Inflammatory Disease and Other Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-06-04 | — | — | US | disclosed |
| US-20150150885-A1 | Compositions and Methods for Treating Neoplasia, Inflammatory Disease and Other Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160317547-A1 | Male Contraceptive Compositions And Methods Of Use | SHBG, CYP19A1, CYP17A1 | ALDH1A1 1692/4885HSD17B10 574/4885TDP1 3591/4885 |
| US-20150150885-A1 | Compositions and Methods for Treating Neoplasia, Inflammatory Disease and Other Disorders | BRPF3, EP300, BRD3 | ALDH1A1 3670/4885HSD17B10 2409/4885TDP1 1447/4885 |
| US-20170145013-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | BRDT, BRD4, BRD3 | ALDH1A1 2824/4885HSD17B10 418/4885TDP1 1397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.